Index Ventures Pledges €10m to Fund Mind-NRG's CNS Candidate
This article was originally published in The Pink Sheet Daily
Executive Summary
The heavily-tranched Series A is Europe's latest example of asset-focused financing.
You may also be interested in...
PanGenetics' NGF Antibody Sale Illustrates Index's Asset-Focused Strategy
The $170 million up-front that Abbott Laboratories ponied up for PanGenetics BV's Phase I PG110 anti-nerve growth factor antibody would rank as the largest down-payment ever for a Phase I project. But even though at first glance the mid-November deal resembles an alliance, it is in fact the acquisition of part of PanGenetics itself, and reveals founding investor Index Ventures' intriguing asset-focused strategy.
Radiopharmaceuticals: A New Frontier In Precision Cancer Therapy
Growing interest in radioligand-based cancer therapies reflects the class’s unique advantages – including the ability to “see what you treat.”
The New Antibodies Revolutionizing Medicine
Nucleic acid-based therapies are poised to revolutionize medicine – just as antibodies did thirty years ago.